Compare Amgen, Inc. (AMGN) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Macy's Inc — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Macy's Inc trades at $22.76 (market cap $5.96B). The key difference: Amgen, Inc. is far larger — about 32.9× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.38%). Which is the better fit depends on your goals.
| AMGN | M | |
|---|---|---|
Market Cap | $196.12B | $5.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $25.96 |
52-Week Low | $271.18 | $11.90 |
Enterprise Value | $241.41B | $9.77B |
Dividend Yield | 2.77% | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Macy's (M) trades at $22.64, down 0.18% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows attractive valuation metrics including a P/E of 9.36 and P/S of 0.27, while profitability metrics like ROE of 14.36% indicate efficient capital use. Recent news highlights Berkshire Hathaway's new 3.04 million-share stake and the company's 'Bold New Chapter' strategy driving comparable sales growth.
The outlook for Macy's is cautiously optimistic with a consensus price target of $24.83 offering ~10% upside. Key opportunities include luxury brand expansion and digital transformation, while risks involve margin pressure from restructuring and competitive retail headwinds. The stock presents a value opportunity if turnaround execution continues successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
